Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Prof. Dingie Janse van Rensburg promoted to Outstanding Professor
2007-11-19

The University of the Free State (UFS) is pleased to announce that Prof. Dingie Janse van Rensburg, Director of the Centre for Health Systems Research and Development has been promoted to Outstanding Professor.

In 1991 the Executive Committee of the Council introduced the category of Outstanding Professor to give recognition to a small group of outstanding academics. Not many academics at the UFS received this status since then.

Prof. Janse van Rensburg has been working at the UFS for 37 years and played a big role in establishing a culture of scientific publication among young and upcoming researchers.

Prof. Janse van Rensburg enjoys extensive national and international recognition as researcher and research manager. He delivered various national and international papers and is involved in a variety of international research projects – some of which were initiated by him. He succeeded in involving a variety of foreign researchers in long term research projects.

In 1993 he established an entrepreneurial research and development centre, which he has sustained for more than 13 years. The centre enjoys recognition nationally as well as internationally as well as credibility in the eyes of the international donor community, within government’s health sphere as well as in peer academic circles.

Prof. Janse van Rensburg has for several years been a grant holder of both the National Research Foundation and the Medical Research Council for research projects on Tuberculosis and HIV/Aids.

During his career at the UFS Prof. Janse van Rensburg received several merit awards and commendations from the UFS and other institutions. These include the Stals Prize in 1993 from the Suid-Afrikaanse Akademie vir Wetenskap en Kuns, a Council Medal from the UFS in 2003, the UFS Centenary Medal in 2004, an award from the Department of Health in 2004 for excellence and continued support of this department, a promotion to Senior Professor from the UFS in 2005 and the Free State Premier’s Excellence Award Gold category in 2006 for excellence in research and development.

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
19 November 2007
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept